Handok Inc
KRX:002390
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Handok Inc
Operating Income
Handok Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Handok Inc
KRX:002390
|
Operating Income
₩3.3B
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-6%
|
|
|
Yuhan Corp
KRX:000100
|
Operating Income
₩104.4B
|
CAGR 3-Years
43%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Operating Income
₩203.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Operating Income
₩257.8B
|
CAGR 3-Years
18%
|
CAGR 5-Years
39%
|
CAGR 10-Years
2%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Operating Income
₩8.5B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-9%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Operating Income
₩20.4B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Handok Inc
Glance View
Handok, Inc. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Seoul, Seoul. The firm's products include Amaryl for diabetes; Tritace for hypertension, myocardial infarction, heart failure and other cardiovascular diseases; Teveten and Triapin for essential hypertension; Munobal for hypertension and stenocardia; Ketas for disturbance of cerebral circulation; Lasix for hypertension and edema, and remedies for skin and others. The company also provides over-the-counter (OTC) pharmaceuticals, healthcare products, as well as medical devices, diagnostic reagents and vaccines. In addition, the Company is involved in the real estates rental business. On July 26, 2013, it changed its name to HANDOK Inc. from Handok Pharmaceuticals Co., LTD.
See Also
What is Handok Inc's Operating Income?
Operating Income
3.3B
KRW
Based on the financial report for Dec 31, 2025, Handok Inc's Operating Income amounts to 3.3B KRW.
What is Handok Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-6%
Over the last year, the Operating Income growth was 511%. The average annual Operating Income growth rates for Handok Inc have been -51% over the past three years , -35% over the past five years , and -6% over the past ten years .
